IP Library Granted Patent US 7,972,793
Granted Patent B2
US 7,972,793 · App. 12/939,049 · Granted Jul 5, 2011

Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype

Assignee: Suregene, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,972,793
App. No.
12/939,049
Granted
Jul 5, 2011
Kind
B2
Abstract

Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.

Claims (10)

1. A method for treating a human subject having or suspected of having a psychotic disorder comprising:

a) selecting a subject that has been determined to have a SULTA1-1 haplotype, wherein the SULTA1-1 haplotype is defined as a haplotype comprising a C allele at rs763120, a combination of an A allele at rs2285162 and a G allele at rs2285167, or the combination of a T allele at rs2285166 and G allele at rs2285167, and treating the subject that has the SULT4A1-1 haplotype with quetiapine or olanzapine; or

b) selecting a subject that has been determined not to have the SULT4A1-1 haplotype and treating the subject that does not have the SULT4A1-1 haplotype with an anti-psychotic treatment other than quetiapine or olanzapine.

2. The method of claim 1 , wherein the subject comprises the SUTL4A1-1 haplotype and the subject is treated with quetiapine.

3. The method of claim 1 , wherein the subject comprises the SUTL4A1-1 haplotype and the subject is treated with olanzapine.

4. The method of claim 1 , wherein the subject does not comprise the SULT4A1-1 haplotype and the subject is treated with an anti-psychotic treatment other than quetiapine or olanzapine.

5. The method of claim 4 , wherein the anti-psychotic treatment other than quetiapine or olanzapine is risperidone.

6. The method of claim 4 , wherein the anti-psychotic treatment other than quetiapine or olanzapine is perphenazine.

7. The method of claim 4 , wherein the anti-psychotic treatment other than quetiapine or olanzapine is ziprasidone.

8. The method of claim 1 , wherein the psychotic disorder is schizophrenia.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2016
From: SUREGENE, LLC
To: CLINICAL REFERENCE LABORATORY, INC.
Reel/Frame 038432/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2010
From: RAMSEY, TIMOTHY L.; BRENNAN, MARK D.
To: SUREGENE, LLC
Reel/Frame 025244/0373 →
Continuity (5)
Continuation In Part 12859056 · Aug 18, 2010
Continuation In Part 12858971 · Aug 18, 2010
Continuation In Part 12646723 · Dec 23, 2009
Continuation In Part 12612438 · Nov 4, 2009
Related Publication 20110105469A1 · May 5, 2011